MUSE 125 MCG
ALPROSTADIL : 125 MCG · DIN 02238592 · PALADIN PHARMA INC.
Health Canada status: CANCELLED PRE MARKET
What is MUSE?
MUSE 125 MCG contains ALPROSTADIL : 125 MCG. It is listed in the Health Canada Drug Product Database under DIN 02238592, held by PALADIN PHARMA INC., supplied as SUPPOSITORY for URETHRAL administration. Health Canada currently lists it as cancelled pre market, status dated 12-Jul-2023. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What else is MUSE called?
The same molecule, ALPROSTADIL, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Bondil | Latin | Norway |
| CAVERJECT | Latin | Brazil, Morocco |
| Caverject Impulse | Latin | Australia |
| Prostin VR | Latin | Bahrain, South Africa |
| Prostivas | Latin | Iceland, Norway |
| Vitaros | Latin | Norway |
| Alprostan | Latin | Slovakia |
| Prostavasin | Latin | Slovakia |
| PROSTIN VR AMP | Latin | Saudi Arabia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 02238592 |
|---|---|
| Brand name | MUSE |
| Generic / active ingredient | ALPROSTADIL : 125 MCG |
| Manufacturer | PALADIN PHARMA INC. |
| Strength | 125 MCG |
| Dosage form | SUPPOSITORY |
| Route of administration | URETHRAL |
| Schedule | Prescription |
| ATC code | G04BE01 ALPROSTADIL |
| AHFS class | 24:12.92 |
| Biosimilar | No |
| Health Canada status | CANCELLED PRE MARKET |
| Status date | 12-Jul-2023 |
| Original market date | 1998-09-24 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02238592 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2238592 |
| Brand name | MUSE |
| Active ingredient / INN | ALPROSTADIL : 125 MCG |
| ATC code | G04BE01 |
| ATC anatomical main group | G — Genito-urinary system and sex hormones |
| ATC therapeutic subgroup | G04 |
| AHFS class | 24:12.92 |
| Health Canada schedule | Prescription |
| Biosimilar biologic | No |
| Market authorization holder | PALADIN PHARMA INC. |
Which pack is which?
| Strength on the label | 125 MCG |
|---|---|
| Dosage form | SUPPOSITORY |
| Route | URETHRAL |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
What can be used instead?
Other Canadian products sharing ATC code G04BE01 ALPROSTADIL. 2 of 10 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| CAVERJECT STERILE POWDER | 20 MCG | LIQUID ; KIT ; POWDER FOR SOLUTION | PFIZER CANADA ULC | MARKETED | DIN 02215756 |
| CAVERJECT STERILE POWDER - PWS 23.2MCG/VIAL | 20 MCG | POWDER FOR SOLUTION | PFIZER CANADA ULC | MARKETED | DIN 02215187 |
| CAVERJECT STERILE POWDER - KIT 11.9MCG /VIAL | 99.1 % | POWDER FOR SOLUTION ; KIT ; LIQUID | PFIZER CANADA ULC | CANCELLED POST MARKET | DIN 02215748 |
| CAVERJECT STERILE POWDER - PWS 11.9MCG/VIAL | 11.9 MCG | POWDER FOR SOLUTION | PFIZER CANADA ULC | CANCELLED POST MARKET | DIN 02215179 |
| MUSE | 1000 MCG | SUPPOSITORY | ENDO OPERATIONS LTD. | CANCELLED POST MARKET | DIN 02238595 |
| MUSE | 250 MCG | SUPPOSITORY | ENDO OPERATIONS LTD. | CANCELLED POST MARKET | DIN 02238593 |
| MUSE | 500 MCG | SUPPOSITORY | ENDO OPERATIONS LTD. | CANCELLED POST MARKET | DIN 02238594 |
| VITAROS | 220 MCG / 100 MG | CREAM | BGP PHARMA ULC | APPROVED | DIN 02359413 |
| VITAROS | 330 MCG / 100 MG | CREAM | BGP PHARMA ULC | APPROVED | DIN 02359421 |
Who else supplies ALPROSTADIL worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. ALPROSTADIL appears in 39 registered pack listings across 13 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does ALPROSTADIL cost around the world?
ALPROSTADIL is listed on 15 national price registers Nexara tracks, across 42 pack listings published on 14 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| Norway | max AUP (pharmacy retail) | 3 | 7 | 07 Sep 2026 |
| Spain | PVP con IVA (public price) | 6 | 6 | 05 Sep 2026 |
| Greece | producer price (ex-factory) | 3 | 3 | 03 Sep 2026 |
| Italy | ex-factory (classe H) | 3 | 3 | 02 Sep 2026 |
| Romania | max producer price | 3 | 3 | 03 Sep 2026 |
| Saudi Arabia | public | 3 | 3 | 01 Sep 2026 |
| Slovakia | categorised final price | 3 | 3 | 02 Sep 2026 |
| Australia | ex-manufacturer | 1 | 2 | 08 Sep 2026 |
| Brazil | preco fabrica (ex-factory ceiling) | 1 | 2 | 02 Sep 2026 |
| Hungary | producer price (ex-factory) | 2 | 2 | 03 Sep 2026 |
| Morocco | PPV (public price) | 1 | 2 | 05 Sep 2026 |
| South Africa | single exit price | 2 | 2 | 01 Sep 2026 |
| United Arab Emirates | public | 1 | 1 | 31 Aug 2026 |
| Bahrain | retail (max) | 1 | 1 | 01 Sep 2026 |
| Iceland | max wholesale | 1 | 1 | 02 Sep 2026 |
| Italy | prezzo al pubblico (classe A) | 1 | 1 | 02 Sep 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled pre market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.